vs
Esperion Therapeutics, Inc.（ESPR）与合众银行（OSBC）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是合众银行的1.8倍（$168.4M vs $93.8M），过去两年合众银行的营收复合增速更高（15.1% vs 10.6%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
合众银行是一家总部位于美国明尼阿波利斯、在特拉华州注册的美国跨国银行机构。截至2025年，它是美国第五大银行，也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性的金融机构，主营银行、投资、抵押等金融服务。
ESPR vs OSBC — 直观对比
营收规模更大
ESPR
是对方的1.8倍
$93.8M
两年增速更快
OSBC
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $93.8M |
| 净利润 | — | $25.6M |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | — |
| 净利率 | — | 27.3% |
| 营收同比 | 143.7% | — |
| 净利润同比 | — | 159.2% |
| 每股收益（稀释后） | $0.32 | $0.48 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPROSBC
| Q1 26 | — | $93.8M | ||
| Q4 25 | $168.4M | $95.2M | ||
| Q3 25 | $87.3M | $95.9M | ||
| Q2 25 | $82.4M | $75.1M | ||
| Q1 25 | $65.0M | $73.1M | ||
| Q4 24 | $69.1M | $73.2M | ||
| Q3 24 | $51.6M | $71.2M | ||
| Q2 24 | $73.8M | $70.8M |
净利润ESPROSBC
| Q1 26 | — | $25.6M | ||
| Q4 25 | — | — | ||
| Q3 25 | $-31.3M | $9.9M | ||
| Q2 25 | $-12.7M | $21.8M | ||
| Q1 25 | $-40.5M | $19.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | $23.0M | ||
| Q2 24 | $-61.9M | $21.9M |
营业利润率ESPROSBC
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | 41.2% | ||
| Q3 25 | -11.4% | 13.6% | ||
| Q2 25 | 8.6% | 38.9% | ||
| Q1 25 | -34.0% | 35.8% | ||
| Q4 24 | -6.4% | 34.7% | ||
| Q3 24 | -31.0% | 41.9% | ||
| Q2 24 | 3.5% | 41.2% |
净利率ESPROSBC
| Q1 26 | — | 27.3% | ||
| Q4 25 | — | — | ||
| Q3 25 | -35.9% | 10.3% | ||
| Q2 25 | -15.4% | 29.0% | ||
| Q1 25 | -62.2% | 27.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | 32.3% | ||
| Q2 24 | -83.9% | 30.9% |
每股收益（稀释后）ESPROSBC
| Q1 26 | — | $0.48 | ||
| Q4 25 | $0.32 | $0.53 | ||
| Q3 25 | $-0.16 | $0.18 | ||
| Q2 25 | $-0.06 | $0.48 | ||
| Q1 25 | $-0.21 | $0.43 | ||
| Q4 24 | $-0.14 | $0.42 | ||
| Q3 24 | $-0.15 | $0.50 | ||
| Q2 24 | $-0.33 | $0.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $115.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $893.3M |
| 总资产 | $465.9M | $6.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPROSBC
| Q1 26 | — | $115.7M | ||
| Q4 25 | $167.9M | $124.0M | ||
| Q3 25 | $92.4M | $116.5M | ||
| Q2 25 | $86.1M | $141.8M | ||
| Q1 25 | $114.6M | $256.1M | ||
| Q4 24 | $144.8M | $99.3M | ||
| Q3 24 | $144.7M | $115.8M | ||
| Q2 24 | $189.3M | $120.9M |
股东权益ESPROSBC
| Q1 26 | — | $893.3M | ||
| Q4 25 | $-302.0M | $896.8M | ||
| Q3 25 | $-451.4M | $866.7M | ||
| Q2 25 | $-433.5M | $718.6M | ||
| Q1 25 | $-426.2M | $694.5M | ||
| Q4 24 | $-388.7M | $671.0M | ||
| Q3 24 | $-370.2M | $661.4M | ||
| Q2 24 | $-344.2M | $619.3M |
总资产ESPROSBC
| Q1 26 | — | $6.8B | ||
| Q4 25 | $465.9M | $6.9B | ||
| Q3 25 | $364.0M | $7.0B | ||
| Q2 25 | $347.1M | $5.7B | ||
| Q1 25 | $324.0M | $5.7B | ||
| Q4 24 | $343.8M | $5.6B | ||
| Q3 24 | $314.1M | $5.7B | ||
| Q2 24 | $352.3M | $5.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ESPROSBC
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $122.3M | ||
| Q3 25 | $-4.3M | $35.9M | ||
| Q2 25 | $-31.4M | $24.2M | ||
| Q1 25 | $-22.6M | $17.8M | ||
| Q4 24 | $-35.0M | $131.5M | ||
| Q3 24 | $-35.3M | $48.5M | ||
| Q2 24 | $-7.2M | $11.6M |
自由现金流ESPROSBC
| Q1 26 | — | — | ||
| Q4 25 | — | $117.8M | ||
| Q3 25 | — | $34.7M | ||
| Q2 25 | — | $23.5M | ||
| Q1 25 | — | $16.2M | ||
| Q4 24 | — | $120.7M | ||
| Q3 24 | $-35.5M | $46.2M | ||
| Q2 24 | $-7.3M | $8.7M |
自由现金流率ESPROSBC
| Q1 26 | — | — | ||
| Q4 25 | — | 123.7% | ||
| Q3 25 | — | 36.2% | ||
| Q2 25 | — | 31.2% | ||
| Q1 25 | — | 22.2% | ||
| Q4 24 | — | 165.0% | ||
| Q3 24 | -68.7% | 64.9% | ||
| Q2 24 | -9.9% | 12.3% |
资本支出强度ESPROSBC
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 4.7% | ||
| Q3 25 | 0.0% | 1.3% | ||
| Q2 25 | 0.0% | 1.1% | ||
| Q1 25 | 0.0% | 2.2% | ||
| Q4 24 | 0.0% | 14.7% | ||
| Q3 24 | 0.3% | 3.3% | ||
| Q2 24 | 0.1% | 4.2% |
现金转化率ESPROSBC
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 3.64× | ||
| Q2 25 | — | 1.11× | ||
| Q1 25 | — | 0.90× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.11× | ||
| Q2 24 | — | 0.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
OSBC
| Net Interest Income | $81.1M | 87% |
| Noninterest Income | $12.6M | 13% |
